Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-18

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter prospective observational study aimed to asses whether a specific prothrombotic platelet phenotype can discern migraine patients with PFO (patent forame ovale) - related symptoms from patients with incidental PFO. The study will also explore additional distinguishing features of causal and incidental PFO using a metabolomics approach. It involves the enrollment of well-characterized patient cohorts and an ex vivo approach using comparative cell biology models that reproduce the most critical aspects of the clinical scenario.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

pLatelEts And MigRaine iN patEnt foRamen Ovale

NCT03521193

Platelet Aggregation, Spontaneous Migraine With Aura Patent Foramen Ovale

COMPLETED NA

NEUROGENETIC AND HEMODYNAMIC OF MIGRAINE AURA AND PFO

NCT07349004

Migraine With Aura

RECRUITING

Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale

NCT06953622

Migraine Patent Foramen Ovale

RECRUITING

Patent Foramen Ovale Closure in Migraine

NCT06192173

Migraine Patent Foramen Ovale

COMPLETED

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

NCT04946734

PFO - Patent Foramen Ovale Migraine

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with PFO, who meet all the inclusion and none of the exclusion criteria, will be enrolled in the study. Patients will undergo percutaneous correction of PFO and the following evaluations as clinical practice:

* thrombophilic screening (factor V and II and MTHFR gene mutation); sampling for homocysteine, Protein C (Prot C), Protein S (Prot S) and antithrombin III assay;
* anatomic evaluation of the SIA (Saccular intracranial aneurysm) by color-doppler TT echocardiogram and intracardiac ultrasound for definition of the anatomy of the fossa ovalis: tunneled appearance; absence of SIA aneurysm; bulging of the SIA; convex right/left SIA aneurysm;
* quantification of right-left intracardiac shunt by CT doppler;
* classification of migraine according to Anzola scale at baseline visit, post PFO correction, at follow-up at 6 and 12 months.

For the purpose of the study, blood sampling will be performed for evaluation of platelet reactivity; oxidative stress, aggregability, and deformability of red blood cells; and isolation of Endothelial Colony Forming Cells (ECFCs) for analysis of endothelial function. The latter in particular will be evaluated in comparison with the endothelial function of 30 subjects without known disease with age \> 18 years, enrolled as a control group.

All analyses will be performed before PFO correction and 180 days after surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Headache PFO - Patent Foramen Ovale

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sigle arm study

Patients with migraine headache with aura (MHA), patent foramen ovale (PFO) and previous neurological event (transient ischemic attack -TIA- or stroke) with clinical indication for percutaneous correction of the defect according to guidelines will be enrolled

blood samples collection

Intervention Type OTHER

patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood samples collection

patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* presence of PFO with right-left shunt at baseline \> 10 MES and during Valsalva \> 20 MES
* previous Stroke or TIA
* positive MRI for ischemic outcomes
* SIA aneurysm or residual Chiari/Eustachian valve network
* thrombophilic screening positivity (MTHFR/prot C/prot S)
* cability to sign informed consent for study participation and adherence to planned clinical follow-ups

Exclusion Criteria

* paroxysmal/refractory atrial fibrillation
* TSA vasculopathy
* left ventricular ejection fraction \<30%
* moderate/severe mitral valve regurgitation
* need for long-term anticoagulant therapy
* allergy or intolerance to antiplatelet therapy
* nickel allergy
* severe chronic kidney disease (GFR \< 30 mL/min)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes